Eli Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding BPL-003, an FDA Breakthrough Therapy-designated intranasal 5-MeO-DMT for treatment-resistant depression, and expanding its neuroscience pipeline with Phase 3-ready neuroplastogen therapies.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Eli Lilly and Company has entered into a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company developing neuroplastogen therapies for treatment-resistant depression (TRD) and other serious mental health disorders. The acquisition marks another strategic expansion of Lilly’s neuroscience pipeline and brings a promising late-stage investigational therapy closer to the company’s global clinical development, regulatory, manufacturing, and commercial capabilities.
The transaction centers on BPL-003 (mebufotenin benzoate), an investigational intranasal synthetic 5-MeO-DMT therapy for treatment-resistant depression that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. By combining AtaiBeckley’s clinical-stage neuroplastogen pipeline with Lilly’s global expertise, the company plans to accelerate the development of new treatment options for patients with limited therapeutic choices.
Addressing an Unmet Need in Treatment-Resistant Depression
Treatment-resistant depression remains one of the greatest challenges in mental health care. Despite the availability of multiple antidepressant therapies, many patients continue to experience persistent symptoms after trying several treatment options, often resulting in substantial impairment in daily functioning, quality of life, and overall health.
Unlike conventional antidepressants that primarily target neurotransmitter signaling, BPL-003 is a synthetic form of 5-MeO-DMT administered intranasally during a supervised in-clinic treatment session. It belongs to a class of investigational neuroplastogens intended to restore synaptic connectivity and promote the growth of new neural connections involved in mood regulation, offering a distinct biological approach to treating depression.
Commenting on the acquisition, Carole Ho, Executive Vice President and President of Lilly Neuroscience, said millions of people continue to live with treatment-resistant depression despite existing therapies. She noted that advancing AtaiBeckley’s investigational pipeline provides an opportunity to address one of the most significant unmet needs in mental health care.
Clinical Progress Behind the Acquisition
The acquisition is driven by encouraging clinical data generated with BPL-003, one of the most advanced neuroplastogen therapies currently in development for treatment-resistant depression.
In a Phase 2b clinical study (NCT05870540), BPL-003 demonstrated rapid and durable reductions in depressive symptoms following a supervised in-clinic treatment session lasting approximately two hours on average. Clinical benefits persisted for several months after treatment. These findings supported the FDA’s decision to grant Breakthrough Therapy Designation, and Phase 3 development activities have already begun.
Beyond BPL-003, the acquisition includes VLS-01, a buccal film formulation of DMT currently being evaluated in an ongoing Phase 2b clinical trial, along with AtaiBeckley’s discovery pipeline of next-generation neuroplastogen compounds. Together, these programs further expand Lilly’s long-term neuroscience research portfolio targeting serious psychiatric disorders.
Financial Terms of the Agreement
Under the agreement, Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, representing an upfront equity value of approximately $2.8 billion.
Shareholders may also receive up to $2.50 per share through contingent value rights (CVRs) linked to future development and regulatory milestones. These include initiation of a Phase 3 clinical trial for VLS-01, U.S. regulatory approval and Drug Enforcement Administration (DEA) rescheduling of BPL-003, and U.S. approval with DEA rescheduling of VLS-01 within specified milestone periods. If all milestones are achieved, the total potential transaction value would reach approximately $3.8 billion.
The acquisition is expected to close during the third quarter of 2026, subject to shareholder approval, customary regulatory clearances, and other closing conditions.
Clinical and Regulatory Significance
Mental health disorders remain among the largest areas of unmet medical need worldwide. At the same time, clinical development is increasingly shifting toward therapies that restore neural connectivity rather than solely altering neurotransmitter signaling. Neuroplastogen therapies have attracted growing interest because of their potential to deliver rapid and durable antidepressant effects after limited treatment sessions.
By acquiring AtaiBeckley, Lilly strengthens its position in this emerging field while expanding a neuroscience pipeline focused on addressing the underlying biology of psychiatric disorders.
What This Means for Patients
For people living with treatment-resistant depression, new therapeutic options cannot come soon enough. Many patients spend years cycling through different medications without achieving adequate symptom control. If ongoing Phase 3 studies confirm the efficacy and safety observed in earlier clinical trials and regulatory approvals are obtained, BPL-003 could provide a new treatment option for patients whose depression has not responded to conventional therapies.
The acquisition also reflects continued industry investment in innovative mental health research and reinforces growing confidence that therapies targeting synaptic plasticity may expand future treatment options for patients with serious psychiatric disorders.
Reference
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.